Saint-Herblain (France) and Dessau-Roßlau (Germany), September 16, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and IDT Biologika today announced they have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva, and considering the current order levels and existing inventories.
DESSAU-ROSSLAU, Germany, March 1, 2022 /PRNewswire/ -- IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses based in Germany, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT's broad range of vector technologies.
Valneva SE, a specialty Vaccine company, and IDT Biologikanhave entered a collaboration for the production of Valneva’s ninactivated COVID-19 vaccine candidate VLA2001. This follows last week’snannouncement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001, over two years.
IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, said that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity (IDIQ) contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus (RSV).
Part of 10-year NIH contract to manufacture vaccines and biologics for infectious diseases